title: A single course of rituximab does not abrogate anti-infliximab antibodies in patients with rheumatoid arthritis.
authors: B J F
authors: BJ
authors: van den Bemt
authors: K
authors: K
authors: Vos
authors: A A
authors: AA
authors: den Broeder
authors: M
authors: M
authors: Blom
authors: R M
authors: RM
authors: Thurlings
authors: G M
authors: GM
authors: Bartelds
authors: S O
authors: SO
authors: Stapel
authors: P
authors: P
authors: Barrera
authors: P P
authors: PP
authors: Tak
authors: M T
authors: MT
authors: Nurmohamed
authors: G-J
authors: GJ
authors: Wolbink
mesh_terms: D000328:Adult; D000368:Aged; D000906:Antibodies / Q000097:blood*; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D000069283:Rituximab
chemical_list: D000906:Antibodies; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D000069283:Rituximab; D000069285:Infliximab